Cassava Sciences, Vertex Pharmaceuticals and Gilead Sciences All Have Good News
Cassava Sciences & Alzheimer's Disease
Cassava Sciences (SAVA) announced the initiation of a second Phase 3 trial of simufilam, its investigational drug for Alzheimer’s disease. This second Phase 3 study is designed to evaluate the safety and efficacy of simufilam over 78 weeks in approximately 1,000 Alzheimer’s . . .
This content is for paid subscribers.
Impacting News November 19, 2021